CDSCO panel to review Serum Institute, Bharat Biotech, Pfizer COVID vaccine applications on December 9

The decision was taken late on Monday evening after the Hyderabad based Bharat Biotech became the third pharmaceutical firm to apply to the Drugs Controller General of India (DCGI) for emergency use authorization for its indigenously developed COVID19 vaccine Covaxin.

Published On 2020-12-08 11:25 GMT   |   Update On 2020-12-08 11:25 GMT
Advertisement

New Delhi: An expert committee of the Central Drugs Standard Control Organisation (CDSCO) will meet on Wednesday to review applications of Pfizer, Serum Institute of India, and Bharat Biotech seeking emergency use authorization for their COVID-19 vaccine candidates, official sources said on Monday night.

The decision was taken late on Monday evening after the Hyderabad-based Bharat Biotech became the third pharmaceutical firm to apply to the Drugs Controller General of India (DCGI) for emergency use authorization for its indigenously developed COVID-19 vaccine Covaxin.

Advertisement

Also Read: CDSCO grants medical device registration to three GOQii wearables

The Indian arm of US pharmaceutical giant Pfizer had on December 4 sought approval for its vaccine from the central drug regulator, after the firm secured such clearance in the UK and Bahrain.

The Pune-based Serum Institute of India sought such a nod for the Oxford COVID-19 vaccine, Covishield, on December 6.

"DCGI has already started processing the applications. The subject expert committee on COVID-19 at CDSCO will deliberate on the applications by Pfizer, Serum Institute of India and Bharat Biotech seeking emergency use authorization for their COVID-19 vaccines on December 9," a source said.

At an all-party meeting on December 4, Prime Minister Narendra Modi had expressed hope that a COVID-19 vaccine may be ready in a few weeks.

Also Read: Initial findings into Serum Institute 'adverse event' did not necessitate halting of trials: Govt

Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News